CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation

This study found that a drug called simurosertib can help prevent a type of cancer treatment resistance in lung and prostate cancers by targeting a protein called CDC7. This is important because it offers a new way to treat cancers which may transform into more aggressive cancer. First author Alvaro Quintanal-Villalonga, PhD, received a Lung Cancer Discovery Award for his work in identifying therapeutic targets for neuroendocrine transformation.